Abstract: An expression cassette, wherein said expression cassette comprises: (a) an ie 1 promoter from white spot syndrome virus or a variant thereof; (b) a nucleic acid sequence encoding an N-terminal gp64 signal peptide or variant thereof, a nucleic acid sequence encoding an antigenic peptide, a nucleic acid encoding a transmembrane region, and a nucleic acid encoding a gp64 cytoplasmic region or variant thereof; in which the promoter is operably linked to the nucleic acid sequence.

Abstract: This invention relates to polynucleotide sequences encoding genes that can confer resistance to the plant pathogen Colletotrichum, which causes anthracnose stalk rot, leaf blight and top dieback in corn and other cereals. It further relates to plants and seeds of plants carrying chimeric genes comprising said polynucleotide sequences, which enhance or confer resistance to the plant pathogen Colletotrichum, and processes of making said plants and seeds. The invention further presents sequences that can be used as molecular markers that in turn can be used to identify the region of interest in corn lines resulting from new crosses and to quickly and efficiently introgress the genes from corn lines carrying said genes into other corn lines that do not carry said genes, in order to make them resistant to Colletotrichum and resistant to stalk rot.

Abstract: A soybean cultivar designated S170013 is disclosed. The invention relates to the seeds of soybean cultivar S170013, to the plants of soybean cultivar S170013, to the plant parts of soybean cultivar S170013, and to methods for producing progeny of soybean cultivar S170013. The invention also relates to methods for producing a soybean plant containing in its genetic material one or more transgenes and to the transgenic soybean plants and plant parts produced by those methods. The invention also relates to soybean cultivars or breeding cultivars, and plant parts derived from soybean cultivar S170013. The invention also relates to methods for producing other soybean cultivars, lines, or plant parts derived from soybean cultivar S170013, and to the soybean plants, varieties, and their parts derived from use of those methods. The invention further relates to hybrid soybean seeds, plants, and plant parts produced by crossing cultivar S170013 with another soybean cultivar.

Abstract: Methods and means are provided to produce positively charged oligosaccharides in the plant cell wall by introducing into said plant cell a Nodulation C protein fused to a heterologous Golgi signal anchor sequence.

Abstract: The present disclosure relates, in some embodiments, to compositions, organisms, systems, and methods for expressing a gene product in a plant using a expression control sequence (ECS) operable in monocots and/or dicots. For example, (i) an isolated nucleic acid may comprise an ECS (e.g., a sugarcane bacilliform virus promoter) and, optionally, an exogenous nucleic acid (ExNA) operably linked to the ECS; (ii) an expression vector may comprise an ECS; an ExNA; and, optionally, a 3? termination sequence, wherein the ECS has promoter activity sufficient to express the ExNA in at least one monocot and at least one dicot; (iii) a microorganism, plant cell, or plant may comprise an isolated nucleic acid; (iv) a method for constitutively expressing an ExNA in a plant (e.g.

Abstract: Provided herein are methods and compositions for treating a subject suffering from a deficiency in ?-L-Iduronidase in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody to a human insulin receptor and an ?-L-Iduronidase. A therapeutically effective systemic dose is based on the specific CNS uptake characteristics of human insulin receptor antibody-?-L-Iduronidase fusion antibodies as described herein.

Abstract: The present invention provides methods of treating a retinal disorder comprising administering an effective amount of a neurotrophic factor to a subject having the retinal disorder. The neurotrophic factors useful in the invention include mesencephalic astrocyte-derived neurotrophic factor (MANF) and conserved dopamine neurotrophic factor (CDNF). The present invention further comprises pharmaceutical compositions and kits containing MANF and CDNF.

Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a Group H nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.

Abstract: A novel maize variety designated X08M611 and seed, plants and plant parts thereof are produced by crossing inbred maize varieties. Methods for producing a maize plant by crossing hybrid maize variety X08M611 with another maize plant are disclosed. Methods for producing a maize plant containing in its genetic material one or more traits introgressed into X08M611 through backcrossing or genetic transformation, and to the maize seed, plant and plant part produced thereby are described. Maize variety X08M611, the seed, the plant produced from the seed, and variants, mutants, and minor modifications of maize variety X08M611 are provided. Methods for producing maize varieties derived from maize variety X08M611 and methods of using maize variety X08M611 are disclosed.

Abstract: The invention provides a nucleic acid construct comprising a sequence that encodes a human telomerase reverse transcriptase (hTERT) protein which is devoid of telomerase catalytic activity and of a nucleolar localization signal. The construct is useful triggering an immune response in a subject, against cells that overexpress telomerase, preferably dysplasia cells or tumor cells.

Abstract: Described herein are methods of delivering a nanoparticle across the blood brain barrier to the brain of a subject by administering to the subject a nanoparticle having a nanoparticle core and a targeting agent. A variety of targeting agents may serve to promote delivery of the described nanoparticle.

Abstract: The invention relates to the soybean variety designated 5PHQP31. Provided by the invention are the seeds, plants and derivatives of the soybean variety 5PHQP31. Also provided by the invention are tissue cultures of the soybean variety 5PHQP31 and the plants regenerated therefrom. Still further provided by the invention are methods for producing soybean plants by crossing the soybean variety 5PHQP31 with itself or another soybean variety and plants produced by such methods.

Abstract: This disclosure concerns compositions and methods for identifying the phytophthora resistant phenotype in soybean. In some embodiments, the disclosure concerns methods for performing marker-assisted breeding and selection of plants carrying one or more determinants of phytophthora resistance in soybean. In some embodiments, the disclosure concerns methods for detecting phytophthora resistance in soybean via the use of an amplification reaction.

Abstract: The purpose of the present invention is to develop a cucumber fruit mottle mosaic virus vector so as to enable a study of gene function through gene silencing phenomenon in Cucurbitaceae plants, which has been difficult to study in the past, and to enable the study in fruits as well through stable expression. Furthermore, the present invention establishes a system that enables expression of a heterologous protein in plants, thereby, for the first time, providing a vector applicable to both the gene silencing phenomenon and protein expression in Cucurbtaceae plants.

Abstract: The invention relates to si RNA molecules and their use in methods and pharmaceutical compositions for inhibiting the expression of the ORAI1 gene. The invention also relates to the use of said si RNAs molecules in the treatment and/or prevention of an eye condition characterized by increased expression and/or activity of ORAI1 gene, preferably said eye condition is conjunctivitis and/or an ocular allergy such as seasonal allergic conjunctivitis, perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, and giant papillary conjunctivitis.

Abstract: The present invention provides DNA molecules and constructs, and their nucleotide sequences, useful for modulating gene expression in plants. Transgenic plants, plant cells, plant parts, and seeds comprising the DNA molecules operably linked to heterologous transcribable polynucleotides are also provided, as are methods of their use.

Abstract: The invention provides a method for ameliorating chronic pain signaling involving transient receptor potential cation channel subfamily V member 1 (TRPV1) by expressing PP1? in neurons. The invention also provides HSV vectors for expressing PP1? within neurons and compositions comprising such vectors.

Abstract: The present invention relates to methods for treating and/or preventing tumors and/or promoting apoptosis in a neoplastic cell comprising contacting the neoplastic cell with an cell-penetrating dominant-negative ATF5 (“CP-d/n-ATF5”), wherein the CP-d/n-ATF5 is capable of inhibiting ATF5 function and/or activity.

Abstract: Influenza viruses for use in preparing human vaccines have traditionally been grown on embryonated hen eggs, although more modern techniques grow the virus in mammalian cell culture e.g. on Vero, MDCK or PER.C6 cell lines. The inventor has realised that the conditions used for influenza virus culture can increase the risk that pathogens other than influenza virus may grow in the cell lines and have identified specific contamination risks. Suitable tests can thus be performed during manufacture in order to ensure safety and avoid iatrogenic infections.

Abstract: According to the invention, there is provided seed and plants of the hybrid corn variety designated CH311019. The invention thus relates to the plants, seeds and tissue cultures of the variety CH311019, and to methods for producing a corn plant produced by crossing a corn plant of variety CH311019 with itself or with another corn plant, such as a plant of another variety. The invention further relates to genetic complements of plants of variety CH311019.

Abstract: A nuclear maize gene is mutated to result in dominant male sterility. Two mutants are provided which impact signal peptide processing. Restoration constructs and methods are provided for use of the dominant male-sterile mutants in producing hybrid seed for male-sterile hybrid plants. Other signal-peptide modifications are provided. Orthologs of the wild type or mutated gene in various species are provided.

Abstract: Summary Problem The purpose of the present invention is to provide: a chiral nucleic acid adjuvant having anti-tumor activity; and an anti-tumor agent. Solution The present invention relates to an adjuvant for anti-tumor agent, wherein the adjuvant comprises oligonucleotides which comprise two to four CpG motif each represented by 5?-X1CpGX2-3? and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3? end side of at least two CpG motifs is connected by phosphorothioate linkage, wherein each nucleic acid at 3? end and 5? end of the oligonucleotide is S type nucleic acid connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an anti-tumor agent containing its adjuvant.

Abstract: The invention relates to a polypeptide for the hydrolytic cleavage of zearalenone and/or at least one zearalenone derivative, said polypeptide being a hydrolase having an amino acid sequence selected from the group consisting of SEQ ID NO: 1-15 or a functional variant thereof, wherein the sequence of the functional variant is at least 40% identical to at least one of the amino acid sequences. The invention also relates to: an additive containing the polypeptide; an isolated polynucleotide that encodes the polypeptide; and a method for the hydrolytic cleavage of zearalenone and/or of at least one zearalenone derivative using the polypeptide.

Abstract: A method of assembling multi-fragment DNA molecule, the method including: 1) constructing a vector system including an acceptor vector A1, a first donor vector B1, and a second donor vector B2, and each of the acceptor vector A1, the second donor vector B2, and the second donor vector B2 including a multiple cloning site; 2) introducing a first target sequence Lm to the first donor vector B1, m being an odd number starting from 1, and introducing a second target sequence Ln to the second donor vector B2, n being an even number starting from 2; and 3) repeating 2) to assemble multiple fragments to yield a multi-fragment DNA molecule.

Abstract: Problem The purpose of the present invention is to provide: a chiral nucleic acid adjuvant having immunity-inducing activity and an immunity-inducing activator. Solution The present invention relates to an adjuvant which comprises oligonucleotides which comprise two to four sequences each represented by 5?-X1CpG X2-3? and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3? end side of at least two CpG motifs is connected by phosphorothioate linkage, wherein each nucleic acids at 3? end and 5? end of the oligonucleotide is S type nucleic acids connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an immunity-inducible activator comprising the adjuvant.

Abstract: The application relates to a composition comprising a stably integrating delivery vector, a modified mammalian thymidylate kinase (tmpk) that increases phosphorylation of a prodrug relative to phosphorylation of the prodrug by wild-type human tmpk, and a detection cassette fused to the tmpk. The application also relates to use of these compositions in methods of treatment of diseases, such as graft versus host disease and cancer.

Abstract: The present invention relates to the specific silencing of the ? (alpha), ? (beta), ? (gamma) and ? (omega)-gliadins of hard wheat for flour by RNA interference (RNAi) through employment of a polynucleotide which is transcribed into an hpRNA (hairpin RNA). Furthermore the present invention additionally relates to a vector, cell, plant or seed comprising the polynucleotide, the expression whereof is specifically directed in particular tissues of wheat seeds through gene expression-regulating sequences such as, for example, the promoter of a gene of ?-gliadins or the promoter of the gene encoding for a D-hordein.

Abstract: This document relates to adenovirus vectors and methods and materials related to using adenovirus vectors. For example, viruses, nucleic acid molecules encoding viruses, cell lines containing viral vectors, and methods for using viruses to deliver nucleic acid to cells in vitro or in vivo are provided. Methods and materials for using adenovirus vectors to induce immune responses and to treat cancer also are provided.

Abstract: Modulators of syndecan-2, such as an antibody to syndecan-2 that cross-links syndecan-2 on the cell surface or a syndecan-2 polypeptide that interferes with syndecan-2 receptor binding, is used to regulate a Th17 mediated disease such as an autoimmune disease, fibrosis or cancer.

Abstract: The subject invention includes methods and plants for controlling European corn borer, said plants comprising a Cry1Ab insecticidal protein and a DIG-3 insecticidal protein to delay or prevent development of resistance by the insect.

Abstract: The present invention aims to provide a promoter showing high expression activity in microorganisms belonging to the genus Mortierella. The present invention provides a polynucleotide which contains any one nucleotide sequence selected from the group consisting of SEQ ID NOs: 1 to 28, or a variant thereof.

Abstract: The present invention relates to treating malignancies such as tumors or cancers by orally administering lyophilized compositions comprising arsenic to a subject in such need. Malignancies include various hematological malignancies, such as acute myeloid leukemia (AML) including acute promyelocytic leukemia (APL), myelodysplastic syndrome (MDS), multiple myeloma (MM) and lymphomas and solid tumors including glioblastoma multiforme and breast cancer. Arsenic treatment has shown great promise in the treatment of several cancers but requires daily intravenous (IV) administration. This invention relates to a novel formulation comprising a lyophilized compositions comprising arsenic. As a result, the formulation facilitates a systemic bioavailability comparable to that of intravenous (IV) administration of arsenic trioxide currently practiced.

Abstract: Growth hormone releasing factor (GHRF) analogs that can be used to induce endogenous growth hormone secretion are disclosed, as well as pharmaceutical compositions comprising the GHRF analogs and methods of using the GHRF analogs.

Abstract: The invention provides compositions and methods related to selective inhibition of PPO11 and use for improving shelf life of a plant or parts thereof. In accordance with the invention, for example, compositions for topical application to a plant or part thereof, are provided that can reduce browning of the plant or part thereof to extend shelf life.

Abstract: Drought-inducible plant promoters are described herein that are useful for expressing drought tolerance factors in plants.

Abstract: A synthetic lentiviral vector construct comprises a genomic RNA packaging enhancer (GRPE) element and lentiviral nucleic acid sequences sufficient for reverse transcription and packaging in a host cell.

Abstract: The present invention provides methods of producing biological products or increasing production of such products through expression in a plant of a bacterial or plant glycolate catabolic cycle gene, such as glycolate dehydrogenease (GDH), glycolate oxidase (GO), or malate synthase (MS) in combination with a plant gene, such as farnesyl diphosphate synthase (FPS), squalene synthase (SQS), or PLAS. Also provided are plants, plants parts and compositions produced through methods of the present invention. The invention leads to two to five fold increase of end product yield.

Abstract: A recombinant expression vector comprising a nucleotide sequence encoding a herpesvirus transactivator, where the nucleotide sequence is operably linked to a herpesvirus control element is provided as are cell lines genetically modified to express a herpesvirus transactivator under the control of a herpesvirus control element. Also provided are methods of identifying agents that disrupt feedback regulation of a herpesvirus transcriptional control element by a herpesvirus transactivator.

Abstract: Genetic constructs capable of manipulating fructan biosynthesis in photosynthetic cells of a plant include a promoter, or functionally active fragment or variant thereof, operatively linked to a nucleic acid encoding a bacterial FT enzyme, or a functionally active fragment or variant thereof. Such constructs can be used in the modification of fructan biosynthesis in plants and, more particularly, to methods of manipulating fructan biosynthesis in photosynthetic cells, for increasing plant biomass and, more particularly, to methods of enhancing biomass yield and/or yield stability, including shoot and/or root growth in a plant, and for enhancing the productivity of biochemical pathways.

Abstract: The present invention refers to a method for controlling undesired vegetation at a plant cultivation site, the method comprising the steps of providing, at said site, a plant that comprises at least one nucleic acid comprising a nucleotide sequence encoding a mutated protoporphyrinogen oxidase (PPO) which is resistant or tolerant to a PPO-inhibiting herbicide by applying to said site an effective amount of said herbicide. The invention further refers to plants comprising mutated PPO enzymes having a substitution at a position corresponding to position Leu397 of SEQ ID NO:2 and an amino acid substitution at a position corresponding to position Phe420 of SEQ ID NO:2, and methods of obtaining such plants.

Abstract: The present invention relates to antibodies or fragments thereof that specifically bind Fc?RIIB, particularly human Fc?RIIB, with greater affinity than the antibodies or fragments thereof bind Fc?RIIA, particularly human Fc?RIIA. The present invention also provides the use of an anti-Fc?RIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.

Abstract: The present invention relates to a hetero-transglycosylase protein having cellulose:xyloglucan endotransglucosylase (CXE) activity in addition to mixed-linkage beta-glucan:xyloglucan endotransglucosylase (MXE) activity. The protein may comprise the amino acid sequence of any one of SEQ ID NOs: 2, 6 and 8 or a functional fragment thereof; or an amino acid sequence having at least 60% sequence identity to any one of SEQ ID NO: 2, 6 and 8, or to SEQ ID NO: 2 from amino acid 22 to 280, to SEQ ID NO: 6 from amino acid 26 to 283, or to SEQ ID NO: 8 from amino acid 29 to 287. The invention furthermore relates to an isolated nucleic acid encoding the protein described herein, a chimeric gene comprising, inter alia, the nucleic acid described herein, a vector comprising said chimeric gene, a host cell comprising said vector or said chimeric gene and an according transgenic plant. Further disclosed herein in are a method of producing a transgenic plant and a method of improving properties of cellulosic material.

Abstract: The present invention provides novel immune-stimulatory polypeptides, and methods for their use and identification.

Abstract: The present invention refers to a method for controlling undesired vegetation at a plant cultivation site, the method comprising the steps of providing, at said site, a plant that comprises at least one nucleic acid comprising a nucleotide sequence encoding a wild-type or a mutated protoporphyrinogen oxidase (PPO) which is resistant or tolerant to a PPO-inhibiting herbicide by applying to said site an effective amount of said herbicide. The invention further refers to plants comprising wild-type or mutated PPO enzymes, and methods of obtaining such plants.

Abstract: The invention relates to an artificial nucleic acid molecule comprising at least one 5?UTR element which is derived from a TOP gene, at least one open reading frame and optionally at least one 3?UTR element comprising a nucleic acid sequence which is preferably derived from the 3?UTR of a gene providing a stable mRNA, such as an albumin gene, or from a variant of the 3?UTR of a gene providing a stable mRNA. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination.

Abstract: Soybean seeds having an ultra-low raffinose and stachyose phenotype. Also disclosed is a mutant allele of soybean designated SG-ULRFO which results in an ultra-low raffinose and stachyose phenotype. The present invention also relates to a soybean seed, a soybean plant and parts of a soybean plant and a soybean hybrid which comprises the mutant allele. Also disclosed are ultra-low raffinose and stachyose soybean seeds having unexpectedly increased germination rates when compared with soybean lines not having a low raffinose and stachyose seed content. Also disclosed are mutant RS3 and RS4 genes with polymorphisms which contribute to the ultra-low raffinose and stachyose phenotype as described in the present invention. The present invention also relates for method of using the soybean seeds and plants of the present invention, to plants parts derived from the present invention, to methods of producing transgenic plants using the plants and seeds of the present invention.

Abstract: Provided herein are biologically active single chain relaxin peptides. In particular the present invention relates to single chain relaxin peptides comprising a B chain derived from relaxin-2, the peptide being truncated by one or more amino acid residues at the N-terminus with respect to the sequence of the B chain of native relaxin-2. Typically the single chain relaxin peptides selectively bind to the RXFP1 receptor.

Abstract: Disclosed are compositions and methods comprising vectors and a reverse genetics competent unit comprising one or more recombinant influenza viruses. Recombinant influenza viruses comprising swine RNA polymerase I promoter are disclosed. Constructs comprising swine RNA polymerase I promoter nucleic acid sequences are also provided. Methods of inducing protecting immunity with the recombinant influenza viruses are disclosed. In certain embodiments, the reverse genetics competent unit comprises pathogenic units necessary for producing pathogens de novo from a nucleotide-based vector for influenza virus in swine.

Abstract: The present invention relates to methods and systems for increasing the affinity of a T cell receptor (TCR) to its ligand by subjecting the TCR gene to somatic hypermutation. The present invention further relates to use of affinity maturated TCRs to create T cells reactive against a selected antigen.

Abstract: The present invention concerns methods and means to produce humanized antibodies from transgenic non-human animals. The invention specifically relates to novel immunoglobulin heavy and light chain constructs, recombination and transgenic vectors useful in making transgenic non-human animals expressing humanized antibodies, transgenic animals, and humanized immunoglobulin preparations.